Dialysis Vascular AccessDialysis Vascular AccessDialysis Vascular AccessDialysis Vascular Access

Transforming the Achilles Heel of Hemodialysis Access into a “Lifeline That Lasts for a Lifetime”Gawing “Lifeline na Tatagal Habambuhay” ang Achilles Heel ng Hemodialysis AccessHimoong “Lifeline nga Molungtad sa Tibuok Kinabuhi” ang Achilles Heel sa Hemodialysis AccessGawan yang “Lifeline a Tumagal king Bie” ing Achilles Heel ning Hemodialysis Access

Plan early. Protect every vessel. Recognize trouble. Rescue wisely. Preserve the next option. No single fistula, graft, or catheter is guaranteed to last forever; a lifetime lifeline is a plan that keeps working access available for as long as you need dialysis.Magplano nang maaga. Protektahan ang bawat ugat. Kilalanin ang problema. Iligtas nang matalino. Ingatan ang susunod na opsyon. Walang fistula, graft, o catheter na garantisadong tatagal habambuhay; ang lifeline habambuhay ay isang plano na nagpapanatili ng gumaganang access hangga't kailangan mo ng dialysis.Pagplano og sayo. Panalipdi ang matag ugat. Ilha ang problema. Luwasa nga maalamon. Bantayi ang sunod nga kapilian. Walay fistula, graft, o catheter nga garantiyado nga molungtad hangtod sa kahangtoran; ang lifeline sa tibuok kinabuhi usa ka plano nga magpabilin sa nagtrabaho nga access samtang kinahanglan nimo ang dialysis.Magplanu kang aga. Protektan me ing balang uyat. Ilala me ing problema. Iligtas me a matalinu. Ingatan me ing susunod a pipiliyan. Alang fistula, graft, o catheter a siguradung tumagal angga king kamatayan; ing lifeline king bie metung yang planu a ilili nang gumagana ing access angga king kailangan mu ing dialysis.

Summary

Planning. Kidney Disease Outcomes Quality Initiative (KDOQI) 2019 and UK Kidney Association (UKKA) 2025 guidance replace “fistula first” with an individualized Life-Plan: protect veins early, choose the access with the patient, and record the next option.

Maintenance. Act on clinical indicators, not routine surveillance. Drug-coated balloons raised 36-month target lesion patency (43.1% versus 28.6%); apixaban after thrombectomy cut 3-month rethrombosis (24.0% versus 40.8%) with more minor bleeding.

Catheters. Taurolidine/heparin locks lowered catheter-related bloodstream infection (CRBSI) from 0.46 to 0.13 per 1,000 catheter-days, adding to core asepsis rather than replacing it. Fish oil, aspirin, and far-infrared therapy did not help.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 21 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
⛔

Go to the emergency room now if your access shows any of these:Pumunta agad sa emergency room kapag may alinman dito ang iyong access:Adto dayon sa emergency room kung naa niini ang imong access:Mako ngeni king emergency room nung atin nanuman kareni ing access mu:

  • Heavy bleeding, or bleeding that does not stop with firm, steady pressure. Keep pressing with a clean cloth and call for emergency help now; do not wait.Malakas na pagdurugo, o pagdurugo na hindi tumitigil kahit mariin at tuloy-tuloy na diniinan. Patuloy na diinan gamit ang malinis na tela at tumawag agad ng emergency na tulong; huwag maghintay.Kusog nga pagdugo, o pagdugo nga dili mohunong bisan sa lig-on ug padayon nga pagpislit. Padayon pagpislit gamit ang limpyo nga panapton ug tawag dayon og emergency nga tabang; ayaw paghulat.Masikan a pamaldugu, o pamaldugu a e tatalakad maski masikan at mipupugtung a pamipindut. Pindutan me pa king malinis a tela at tumawag kang emergency a saup ngeni; ali ka maglaus.
  • The buzz (thrill) is gone or suddenly very different, and you cannot feel it anywhere along the access.Nawala ang buzz (thrill) o biglang ibang-iba, at hindi mo na ito maramdaman saanman sa access.Nawala ang buzz (thrill) o kalit nga lahi kaayo, ug dili na nimo mabati bisan asa sa access.Mewala ing buzz (thrill) o biglang aliwa, at e mu na marandaman nanu man king access.
  • The hand on the access side is cold, pale or blue, very painful, numb, or weak.Malamig, maputla o kulay-ube, sobrang sakit, manhid, o mahina ang kamay sa panig ng access.Bugnaw, luspad o asul, sakit kaayo, manhid, o huyang ang kamot sa kilid sa access.Maranun, maputla o kule-ube, masakit dili, manhid, o malatang ing gamat king lugal ning access.
  • Fever or shaking chills, especially during or after dialysis, or redness, pus, or swelling at the access or catheter.Lagnat o nanginginig na ginaw, lalo na habang o pagkatapos mag-dialysis, o pamumula, nana, o pamamaga sa access o catheter.Hilanat o nagkurog nga katugnaw, labi na samtang o human sa dialysis, o pagpula, nana, o paghubag sa access o catheter.Lagnat o makikurug a malamig, lalu na kabang o kaybat ning dialysis, o pamula, nana, o pamalaga king access o catheter.
  • Sudden trouble breathing, chest pain, or a racing heart.Biglang hirap huminga, pananakit ng dibdib, o napakabilis na tibok ng puso.Kalit nga kalisod sa pagginhawa, sakit sa dughan, o paspas kaayo nga pitik sa kasingkasing.Biglang kasakitan king manginawa, sakit king salu, o malagua dili a pitik ning pusu.

No calculator, chart, or checklist on this page should delay emergency care. Call your dialysis unit on the way.Walang calculator, tsart, o checklist dito na dapat magpaantala sa emergency care. Tawagan ang dialysis unit habang papunta.Walay calculator, tsart, o checklist dinhi nga angay molangan sa emergency care. Tawagi ang dialysis unit samtang padulong.Alang calculator, tsart, o checklist keni a dapat mamaburi king emergency care. Tawagan me ing dialysis unit kabang mako.

💡

The one-minute answerAng sagot sa isang minutoAng tubag sa usa ka minutoIng sagot king metung a minutu

  1. Hemodialysis needs a way to move a lot of blood to the machine and back. That way in and out is your access: a fistula, a graft, or a catheter.Kailangan ng hemodialysis ng daan para maraming dugo ang dumaan sa makina at bumalik. Ang daang iyon ay ang iyong access: fistula, graft, o catheter.Ang hemodialysis nanginahanglan og agianan aron daghang dugo ang moagi sa makina ug mobalik. Kana nga agianan mao ang imong access: fistula, graft, o catheter.Ing hemodialysis kailangan ne ing dalan para dakal a daya ing malyari mako king makina at mibalik. Ita ing access mu: fistula, graft, o catheter.
  2. No single access is guaranteed to last forever. A lifeline that lasts a lifetime means a plan: the access you have now, how to protect it, and what comes next if it fails.Walang iisang access na garantisadong tatagal habambuhay. Ang lifeline na tatagal habambuhay ay isang plano: ang access mo ngayon, paano ito protektahan, at ano ang susunod kung pumalya ito.Walay usa ka access nga garantiyado nga molungtad hangtod sa kahangtoran. Ang lifeline nga molungtad sa tibuok kinabuhi usa ka plano: ang imong access karon, unsaon pagpanalipod, ug unsa ang sunod kung mapakyas kini.Alang metung a access a siguradung mamalyaring tumagal angga king kamatayan. Ing lifeline a tumagal ya king bie mu metung yang plano: ing access mu ngeni, makananu meng protektan, at nanu ing susunod nung mapalya ya.
  3. Start early, protect your arm veins, check your access every day, and speak up fast when something changes.Magsimula nang maaga, protektahan ang mga ugat sa braso, suriin ang access araw-araw, at magsalita agad kapag may nagbago.Sugdi og sayo, panalipdi ang mga ugat sa bukton, susiha ang access matag adlaw, ug isulti dayon kung naay nausab.Mumpisa kang aga, protektan me ding uyat king takiag mu, lawan me ing access aldo-aldo, at sabyan mu agad nung atin miyaliwa.

Paalala: draft pa ang salin na ito at hinihintay ang pagsusuri ng katutubong tagapagsalita. Ang Ingles na bersyon ang sinuri.Pahinumdom: draft pa kini nga hubad ug naghulat sa pagsusi sa lumad nga mamumulong. Ang Ingles nga bersyon ang nasusi.Paalala: draft pa ing salin a iti at manaya king pamanigaral ning katutubung manyalita. Ing Ingles a bersyun ing linawe.

What a dialysis access is, and why it is your lifelineAno ang dialysis access, at bakit ito ang iyong lifelineUnsa ang dialysis access, ug nganong kini ang imong lifelineNanu ing dialysis access, at nokarin ya ing lifeline mu

Think of your access as a busy bridge between your body and the dialysis machine. Three to four hours, three times a week, about 300 milliliters of blood a minute has to cross it and come back. A normal arm vein is too small and too slow for that traffic, so the access team builds a stronger crossing.Isipin ang iyong access bilang isang abalang tulay sa pagitan ng katawan at ng dialysis machine. Tatlo hanggang apat na oras, tatlong beses isang linggo, mga 300 mililitro ng dugo kada minuto ang dumadaan dito at bumabalik. Masyadong maliit at mabagal ang karaniwang ugat sa braso, kaya gumagawa ang access team ng mas matibay na tawiran.Hunahunaa ang imong access isip busy nga taytayan tali sa imong lawas ug sa dialysis machine. Tulo hangtod upat ka oras, tulo ka beses sa usa ka semana, mga 300 mililitro sa dugo kada minuto ang moagi niini ug mobalik. Gamay ra kaayo ug hinay ang naandang ugat sa bukton, mao nga ang access team mohimo og mas lig-on nga tabokanan.Isipan me ing access mu antimong matau a tete king pagitan ning katawan mu at ning dialysis machine. Atlu angga apat a oras, atlung beses king metung a dominggu, mga 300 mililitru a daya balang minutu ing dadalan keti at mibabalik. Malati at mabagal ing karaniwan a uyat king takiag, kaya gagawa ing access team ning matibe a pamagliban.

Diagram of blood leaving the arm through the access, passing through the dialysis machine filter, and returning to the arm.

Blood leaves through one needle or catheter line, is cleaned in the machine, and returns through the other. The access is the bridge that makes this possible.Lumalabas ang dugo sa isang karayom o linya ng catheter, nililinis sa makina, at bumabalik sa kabila. Ang access ang tulay na nagpapagana nito.Mogawas ang dugo sa usa ka dagom o linya sa catheter, limpyohan sa makina, ug mobalik sa pikas. Ang access mao ang taytayan nga naghimo niini nga posible.Lulwal ya ing daya king metung a karayum o linya ning catheter, linisan ya king makina, at mibalik king kabila. Ing access ing tete a magpagana kaniti.

AV
Arteriovenous: joining an artery to a vein

© renalcarematters.com

AccessAccessAccessAccessHow it is madePaano ginagawaGiunsa paghimoMakananu gagawanWhat to knowDapat malamanAngay mahibaloanDapat mong abalu
Arteriovenous fistula (AVF)Arteriovenous fistula (AVF)Arteriovenous fistula (AVF)Arteriovenous fistula (AVF)A surgeon joins an artery directly to a vein in your arm. Your own vein grows thicker and stronger.Pinagdurugtong ng siruhano ang arterya at ugat sa braso. Lumalaki at tumitibay ang sarili mong ugat.Gidugtong sa siruhano ang arterya ug ugat sa bukton. Modako ug molig-on ang imong kaugalingong ugat.Pagdugtungan ning siruhanu ing arterya at uyat king takiag mu. Mamaragul at titibe ing sariling uyat mu.Usually needs weeks to months to be ready. When it works well, it often lasts long with fewer infections.Karaniwang ilang linggo hanggang buwan bago magamit. Kapag maayos, madalas itong tumatagal at mas kaunti ang impeksyon.Kasagaran pila ka semana hangtod bulan una magamit. Kung maayo, kasagaran molungtad ug mas gamay ang impeksyon.Karaniwan pilan a dominggu angga bulan bayu magamit. Nung mayap, kalimitan tumagal ya at mas kaunti ing impeksyun.
Arteriovenous graft (AVG)Arteriovenous graft (AVG)Arteriovenous graft (AVG)Arteriovenous graft (AVG)A soft tube is placed under the skin to connect an artery and a vein.Isang malambot na tubo ang inilalagay sa ilalim ng balat para pagdugtungin ang arterya at ugat.Usa ka humok nga tubo ang ibutang ilalom sa panit aron idugtong ang arterya ug ugat.Metung a malambut a tubu ing ibili king lalam ning balat para pagdugtungan ing arterya at uyat.Ready sooner than most fistulas. Tends to narrow or clot more often, so it may need more procedures.Mas maagang magagamit kaysa sa karamihan ng fistula. Mas madalas kumitid o mamuo ang dugo, kaya maaaring mas maraming procedure.Mas sayo magamit kaysa kadaghanan sa fistula. Mas kanunay mokitid o motuhop ang dugo, mao nga basin mas daghang procedure.Mas aga yang magamit kesa king dakal a fistula. Mas malimit yang kumitid o mamuu ing daya, kaya malyaring mas dakal a procedure.
Central venous catheter (CVC)Central venous catheter (CVC)Central venous catheter (CVC)Central venous catheter (CVC)A soft tube goes into a large vein in the neck or chest, with two ends outside the skin.Isang malambot na tubo ang ipinapasok sa malaking ugat sa leeg o dibdib, na may dalawang dulo sa labas ng balat.Usa ka humok nga tubo ang isulod sa dakong ugat sa liog o dughan, nga adunay duha ka tumoy sa gawas sa panit.Metung a malambut a tubu ing pasok king maragul a uyat king batal o salu, a atin adwang dulu king lual ning balat.Usable right away. Germs can travel along it, so it carries a higher infection risk; usually it is a bridge to a fistula, graft, transplant, or peritoneal dialysis.Magagamit agad. Maaaring dumaan ang mikrobyo rito kaya mas mataas ang panganib ng impeksyon; karaniwan itong pansamantalang tulay patungo sa fistula, graft, transplant, o peritoneal dialysis.Magamit dayon. Ang mikrobyo makaagi niini mao nga mas taas ang peligro sa impeksyon; kasagaran kini usa ka temporaryong taytayan padulong sa fistula, graft, transplant, o peritoneal dialysis.Magamit ya agad. Malyaring dalanan ning mikrobyu, kaya mas matas ing peligru ning impeksyun; kalimitan pansamantalang tete ya pasibayu king fistula, graft, transplant, o peritoneal dialysis.

An access is not the same as kidney treatment choices. Peritoneal dialysis (PD), which uses the lining of the belly instead of a blood access, a kidney transplant, and supportive care without dialysis are all valid paths. Your team may move between them over the years, and good access planning keeps those doors open.Hindi pareho ang access at ang pagpili ng gamutan sa bato. Ang peritoneal dialysis (PD), na gumagamit ng lining ng tiyan sa halip na dugo, kidney transplant, at supportive care na walang dialysis ay pawang tamang landas. Maaaring lumipat ang iyong team sa pagitan ng mga ito sa paglipas ng taon, at ang maayos na plano sa access ay nagpapanatiling bukas ng mga pintong iyon.Ang access dili parehas sa pagpili sa pagtambal sa kidney. Ang peritoneal dialysis (PD), nga naggamit sa lining sa tiyan imbes nga dugo, kidney transplant, ug supportive care nga walay dialysis tanan husto nga dalan. Mahimong mobalhin ang imong team taliwala niini sa paglabay sa mga tuig, ug ang maayong plano sa access nagpabilin nga bukas sa maong mga pultahan.Ing access e pareu king pamamili ning panulu king batu. Ing peritoneal dialysis (PD), a gagamit king lining ning atian kesa king daya, ing kidney transplant, at ing supportive care a alang dialysis, deti ngan tamang dalan. Malyaring mipalit ing team mu king pagitan dareti king milabas a banwa, at ing mayap a plano king access ilili nang makabuklat dening pasbul a ita.

The Achilles heel: why accesses narrow, clot, or get infectedAng kahinaan: bakit kumikitid, namumuo, o naiimpeksyon ang accessAng kahuyang: nganong mokitid, motuhop, o ma-impeksyon ang accessIng kalatan: nokarin kumikitid, mamuu, o ma-impeksyun ing access

A fistula carries far more blood, far faster, than a vein was built for. The vein wall answers that pressure the way skin answers rubbing: it thickens. Usually that helps. But in some spots, often near the surgical join or where the vein bends, the thickening grows inward and narrows the channel. That narrowing is called a stenosis. When flow slows enough, blood can clot and block the access (thrombosis).Mas maraming dugo at mas mabilis ang dinadala ng fistula kaysa sa kaya ng isang karaniwang ugat. Sumasagot ang pader ng ugat sa presyon gaya ng balat na nakikiskis: kumakapal ito. Kadalasan nakakatulong iyon. Pero sa ilang bahagi, madalas malapit sa dugtungan o kung saan kumukurba ang ugat, kumakapal ito papaloob at kumikitid ang daluyan. Tinatawag itong stenosis. Kapag sapat nang bumagal ang daloy, maaaring mamuo ang dugo at barahan ang access (thrombosis).Ang fistula nagdala og mas daghang dugo ug mas paspas kaysa sa kaya sa naandang ugat. Mosanong ang bungbong sa ugat sa presyon sama sa panit nga gikiskis: mobaga kini. Kasagaran makatabang kana. Apan sa pipila ka bahin, kasagaran duol sa dugtungan o diin moliko ang ugat, mobaga kini pasulod ug mokitid ang agianan. Gitawag kini nga stenosis. Kung igo nang mohinay ang dagan, motuhop ang dugo ug bararan ang access (thrombosis).Mas dakal a daya at mas malagua ing dadalan ning fistula kesa king kaya ning karaniwan a uyat. Sasagut ing pader ning uyat king presyun antimong balat a kikiskisan: kakapal ya. Kalimitan makasaup ita. Oneng king nanung lugal, malimit malapit king dugtungan o nung nu kukurba ing uyat, kakapal ya paluub at kikitid ing dalan. Aus deng stenosis iti. Nung sapat nang bumagal ing agus, malyaring mamuu ing daya at sarakan ing access (thrombosis).

Cut-away of a fistula showing the vein wall thickening inward near the join, narrowing the channel and slowing blood flow.

Fast, swirling blood near the surgical join can make the vein wall thicken inward. The channel narrows, flow slows, and a clot can form.Ang mabilis at umiikot na dugo malapit sa dugtungan ay maaaring magpakapal ng pader ng ugat papaloob. Kumikitid ang daluyan, bumabagal ang daloy, at maaaring mamuo ang dugo.Ang paspas ug nagtuyok nga dugo duol sa dugtungan makapabaga sa bungbong sa ugat pasulod. Mokitid ang agianan, mohinay ang dagan, ug motuhop ang dugo.Ing malagua at mikikulikut a daya malapit king dugtungan malyaring mamakapal king pader ning uyat paluub. Kikitid ing dalan, bubagal ing agus, at malyaring mamuu ing daya.

© renalcarematters.com

Other problems are different and need different fixes: a new fistula that never grows big enough (non-maturation), needle injuries and bruising, bulges in the vein (aneurysms), infection, a hand that gets too little blood (steal), narrowing of the big chest veins after catheters or pacemaker wires, and, rarely, a very high-flow fistula that overworks the heart. None of these means you or your nurse did something wrong. Many are simply how blood vessels react to dialysis.Iba-iba ang ibang problema at iba ang lunas: bagong fistula na hindi lumalaki nang sapat (non-maturation), sugat at pasa mula sa karayom, umbok sa ugat (aneurysm), impeksyon, kamay na kulang sa dugo (steal), pagkitid ng malalaking ugat sa dibdib pagkatapos ng catheter o kawad ng pacemaker, at bihira, fistula na napakalakas ng daloy kaya napapagod ang puso. Wala sa mga ito ang nangangahulugang ikaw o ang nurse ang nagkamali. Marami ay reaksyon lang ng ugat sa dialysis.Lahi-lahi ang ubang problema ug lahi ang tambal: bag-ong fistula nga dili modako og igo (non-maturation), samad ug pasa gikan sa dagom, bukol sa ugat (aneurysm), impeksyon, kamot nga kulang sa dugo (steal), pagkitid sa dagkong ugat sa dughan human sa catheter o alambre sa pacemaker, ug panagsa, fistula nga kusog kaayo ang dagan mao nga mapagod ang kasingkasing. Walay usa niini nga nagpasabot nga ikaw o ang nurse ang nasayop. Daghan niini reaksyon lang sa ugat sa dialysis.Aliwa-aliwa la ding aliwang problema at aliwa ing panulu: bayung fistula a e mamaragul king sapat (non-maturation), sugat at pasa ning karayum, ambun king uyat (aneurysm), impeksyun, gamat a kulang king daya (steal), pamikitid ding maragul a uyat king salu kaybat ning catheter o kawad ning pacemaker, at bihira, fistula a masikan dili ing agus kaya mapapagal ing pusu. Alang metung kareti a buri nang sabyan a ika o ing nurse ing mekamali. Dakal kareti reaksyun mu ning uyat king dialysis.

Protect your veins today for the access you may need laterProtektahan ang iyong mga ugat ngayon para sa access na maaaring kailanganin moPanalipdi ang imong mga ugat karon alang sa access nga basin kinahanglanon nimoProtektan me ding uyat mu ngeni para king access a malyaring kailangan mu

A fistula needs a healthy vein. Every needle stick, drip line, or long catheter in your arm can scar the veins you will need. If your kidney function is falling, or your doctor has mentioned dialysis, start protecting one arm now, usually the one you do not write with.Kailangan ng fistula ang malusog na ugat. Bawat turok ng karayom, swero, o mahabang catheter sa braso ay maaaring magpeklat sa ugat na kakailanganin mo. Kung bumababa ang kidney function mo o nabanggit na ng doktor ang dialysis, simulan nang protektahan ang isang braso, karaniwan ang hindi mo ginagamit sa pagsulat.Ang fistula nanginahanglan og himsog nga ugat. Matag tusok sa dagom, swero, o taas nga catheter sa bukton makapaplat sa ugat nga imong kinahanglanon. Kung nagkaubos ang kidney function o nahisgotan na sa doktor ang dialysis, sugdi na karon pagpanalipod sa usa ka bukton, kasagaran ang dili nimo gamiton sa pagsulat.Kailangan ning fistula ing masalikutan a uyat. Balang tusuk ning karayum, swero, o malawak a catheter king takiag malyaring mamaging piklat king uyat a kailangan mu. Nung bubaba ing kidney function mu o mebanggit na ning doktor ing dialysis, mumpisa na ngeni a protektan ing metung a takiag, karaniwan ing e mu gagamitan king panyulat.

DoGawinBuhataGawan

  • Ask for blood tests and drips on the hand or arm your team is not saving.Hilingin na sa kamay o brasong hindi inilalaan ng team gawin ang blood test at swero.Hangyoa nga sa kamot o bukton nga dili gitagana sa team himuon ang blood test ug swero.Pakisabyan mu a king gamat o takiag a e lilinan ning team gawan ing blood test at swero.
  • Tell every new nurse or doctor: "Please save this arm for my dialysis access."Sabihin sa bawat bagong nurse o doktor: "Pakiusap, ilaan ang brasong ito para sa aking dialysis access."Isulti sa matag bag-ong nurse o doktor: "Palihug, itagana kini nga bukton para sa akong dialysis access."Sabyan mu king balang bayung nurse o doktor: "Pakiusap, lilinan ye ing takiag a iti para king dialysis access ku."
  • Ask early how your kidney function is trending and when to meet the access surgeon.Magtanong nang maaga kung paano ang takbo ng kidney function at kailan makikipagkita sa access surgeon.Pangutana og sayo kung unsa ang dagan sa kidney function ug kanus-a makigkita sa access surgeon.Magtanung kang aga nung makananu ing takbu ning kidney function mu at kapilan makilala ing access surgeon.

Avoid in the saved armIwasan sa inilaang brasoLikayi sa gitagana nga buktonPangilagan king linilinan a takiag

  • Blood draws, drips, and blood pressure cuffs, unless there is no other choice.Pagkuha ng dugo, swero, at blood pressure cuff, maliban kung walang ibang pagpipilian.Pagkuha og dugo, swero, ug blood pressure cuff, gawas kung walay laing kapilian.Pamangua daya, swero, at blood pressure cuff, liban nung alang aliwang pipiliyan.
  • A peripherally inserted central catheter (PICC) line. Ask whether another kind of line can be used.Peripherally inserted central catheter (PICC) line. Itanong kung may ibang uri ng linya na maaaring gamitin.Peripherally inserted central catheter (PICC) line. Pangutana kung naay laing klase sa linya nga magamit.Peripherally inserted central catheter (PICC) line. Itanung mu nung atin aliwang klasi ning linya a malyaring gamitan.
  • Tight sleeves, watches, or bags hanging on the arm once a fistula or graft is made.Masisikip na manggas, relo, o bag na nakasabit sa braso kapag may fistula o graft na.Hugot nga bukton sa sinina, relo, o bag nga gibitay sa bukton kung naa nay fistula o graft.Masikip a manggas, relo, o bag a makasabit king takiag nung atin ng fistula o graft.
Illustration of a person holding up one arm marked as saved for dialysis access, with a blood draw done on the other hand instead.

Save one arm. Use the other hand or arm for blood tests and drips whenever possible.Ilaan ang isang braso. Gamitin ang kabilang kamay o braso para sa blood test at swero hangga't maaari.Itagana ang usa ka bukton. Gamita ang pikas kamot o bukton para sa blood test ug swero kutob sa mahimo.Lilinan me ing metung a takiag. Gamitan me ing kabilang gamat o takiag para king blood test at swero nung malyari.

© renalcarematters.com

Your team can estimate how fast your kidneys are heading toward failure with a simple score called the Kidney Failure Risk Equation (KFRE). When the 2-year risk is high, international kidney guidance suggests it is time to prepare for treatment, which includes planning the access.Matatantiya ng team kung gaano kabilis papalapit sa pagpalya ang bato gamit ang simpleng score na Kidney Failure Risk Equation (KFRE). Kapag mataas ang 2-taong panganib, iminumungkahi ng pandaigdigang gabay na oras nang maghanda, kasama ang pagpaplano ng access.Mabanabana sa team kung unsa ka paspas padulong sa pagkapakyas ang kidney gamit ang simple nga score nga Kidney Failure Risk Equation (KFRE). Kung taas ang 2-ka-tuig nga peligro, ang internasyonal nga giya nagsugyot nga panahon na sa pag-andam, lakip ang pagplano sa access.Malyaring tantyan ning team nung makananu kalagua papalapit king pamalya ing batu king simpling score a Kidney Failure Risk Equation (KFRE). Nung matas ing peligru king 2 banwa, ing pandaigdigang giya mangisabi a panaun nang maghanda, kayabe ing pamaplanu king access.

Choosing an access together with your teamPagpili ng access kasama ang iyong teamPagpili sa access uban sa imong teamPamili ning access kayabe ing team mu

The old rule was "fistula first for everyone." Current guidance from the United States and the United Kingdom asks for something better: the right access, for the right person, at the right time, chosen with you. A fistula is often the best long-term option, but not always. For someone who needs dialysis soon, has small veins, or has other health priorities, a graft, a catheter for a while, or peritoneal dialysis can be the wiser choice.Ang dating panuntunan ay "fistula muna para sa lahat." Ang kasalukuyang gabay mula sa Estados Unidos at United Kingdom ay humihingi ng mas mabuti: ang tamang access, para sa tamang tao, sa tamang panahon, na pinipili kasama ka. Madalas na fistula ang pinakamahusay sa pangmatagalan, pero hindi palagi. Para sa nangangailangan ng dialysis agad, may maliliit na ugat, o may ibang priyoridad sa kalusugan, maaaring mas matalino ang graft, catheter muna, o peritoneal dialysis.Ang daan nga lagda mao ang "fistula una para sa tanan." Ang karon nga giya gikan sa Estados Unidos ug United Kingdom nangayo og mas maayo: ang husto nga access, para sa husto nga tawo, sa husto nga panahon, nga gipili uban kanimo. Kasagaran fistula ang labing maayo sa dugay nga panahon, apan dili kanunay. Para sa nanginahanglan og dialysis dayon, gagmay og ugat, o adunay laing prayoridad sa panglawas, mahimong mas maalamon ang graft, catheter una, o peritoneal dialysis.Ing matuang patakaran "fistula muna para king sablang tau." Ing gabay ngeni ibat king Estados Unidos at United Kingdom ali mas mayap: ing tamang access, para king tamang tau, king tamang panaun, a pipiliyan kayabe ka. Kalimitan fistula ing pekamayap king malawak a panaun, oneng e pane. Para king kailangan agad ning dialysis, malati ding uyat, o atin aliwang priyoridad king salikut, malyaring mas matalinu ing graft, catheter pamu, o peritoneal dialysis.

Side-by-side comparison of a fistula, a graft, and a neck catheter, with a simple timeline bar under each showing how soon it can be used.

Fistula, graft, and catheter each trade speed, durability, and infection risk differently. There is no single winner for everyone.Ang fistula, graft, at catheter ay may kanya-kanyang kapalit sa bilis, tibay, at panganib ng impeksyon. Walang iisang panalo para sa lahat.Ang fistula, graft, ug catheter adunay kaugalingong baylo sa kapaspas, kalig-on, ug peligro sa impeksyon. Walay usa ka mananaog para sa tanan.Ing fistula, graft, at catheter atin ngan kaniang kapalit king kalagua, katibe, at peligru ning impeksyun. Alang metung a manalu para king sablang tau.

© renalcarematters.com

Good questions to bring: How soon will I need dialysis? Which arm, and why? How long until the access can be used, and what is the backup? How many procedures might it need? What will it cost me, and what does PhilHealth (Philippine Health Insurance Corporation) or my health maintenance organization (HMO) cover? Could peritoneal dialysis or a transplant fit my life?Magandang itanong: Gaano kaaga ko kailangan ng dialysis? Aling braso, at bakit? Gaano katagal bago magamit ang access, at ano ang backup? Ilang procedure ang maaaring kailanganin? Magkano ang gagastusin ko, at ano ang sakop ng PhilHealth o HMO? Bagay ba sa buhay ko ang peritoneal dialysis o transplant?Maayong pangutana: Kanus-a nako kinahanglan ang dialysis? Asa nga bukton, ug ngano? Unsa kadugay una magamit ang access, ug unsa ang backup? Pila ka procedure ang basin kinahanglan? Pila ang akong gastohon, ug unsa ang sakop sa PhilHealth o HMO? Haom ba sa akong kinabuhi ang peritoneal dialysis o transplant?Mayap a itanung: Kapilan ku kailangan ing dialysis? Nanung takiag, at nokarin? Makanu katagal bayu magamit ing access, at nanu ing backup? Pilan a procedure ing malyaring kailangan? Makanu ing gastusan ku, at nanu ing sakup ning PhilHealth o HMO? Bage ya king bie ku ing peritoneal dialysis o transplant?

From surgery to first needles: giving a new fistula time to growMula operasyon hanggang unang karayom: bigyan ng panahon ang bagong fistulaGikan sa operasyon hangtod sa unang dagom: hatagi og panahon ang bag-ong fistulaIbat king operasyun angga king mumunang karayum: bien yang panaun ing bayung fistula

A new fistula has to mature: the vein widens and its wall strengthens until it can take two needles safely, session after session. A date on the calendar alone does not decide this. Your team checks how it looks and feels, often with an ultrasound, and the first needling is planned by an experienced nurse.Kailangang mag-mature ang bagong fistula: lumalapad ang ugat at tumitibay ang pader hanggang kaya na nito ang dalawang karayom nang ligtas, sesyon kada sesyon. Hindi lang petsa sa kalendaryo ang nagpapasya. Sinusuri ng team kung paano ito tingnan at damhin, madalas gamit ang ultrasound, at pinaplano ng bihasang nurse ang unang turok.Kinahanglan mo-mature ang bag-ong fistula: molapad ang ugat ug molig-on ang bungbong hangtod makaya na niini ang duha ka dagom nga luwas, matag sesyon. Dili lang petsa sa kalendaryo ang modesisyon. Susihon sa team kung unsa kini tan-awon ug batyon, kasagaran gamit ang ultrasound, ug ang unang tusok planohon sa batid nga nurse.Kailangan mag-mature ing bayung fistula: lalapad ing uyat at titibe ing pader angga king kaya na ning adwang karayum a ligtas, balang sesyun. E mu petsa king kalendaryu ing magdesisyun. Lalawan ning team nung makananu ya lawan at damdaman, malimit king ultrasound, at ing mumunang tusuk planuan ning batid a nurse.

Timeline from surgery day through healing, check-ups, ultrasound, first gentle needling, and dependable two-needle dialysis.

Healing, checking, first gentle needles, then dependable use. Each step has an owner and a review date.Paggaling, pagsusuri, unang maingat na karayom, saka maaasahang paggamit. May taong responsable at petsa ng pagsusuri ang bawat hakbang.Pag-ayo, pagsusi, unang mainampingong dagom, unya kasaligang paggamit. Matag lakang adunay tag-iya ug petsa sa pagsusi.Pamagumpaya, pamanyalikut, mumunang maingat a karayum, kaybat masasaligan a pamamagamit. Balang dalan atin taung responsable at petsa ning pamanyalikut.

© renalcarematters.com

Ask your surgeon whether simple hand-squeeze exercises are right for you. Small studies show they can widen arm veins, but they have not been proven to make fistulas mature more often, so treat them as a helper, not a guarantee.Itanong sa siruhano kung angkop sa iyo ang simpleng pagpisil ng kamay. Ipinapakita ng maliliit na pag-aaral na maaari nitong palaparin ang ugat sa braso, pero hindi pa napapatunayan na mas madalas mag-mature ang fistula, kaya ituring itong katulong, hindi garantiya.Pangutana sa siruhano kung angay nimo ang simple nga pagpiga sa kamot. Gipakita sa gagmay nga pagtuon nga makapalapad kini sa ugat sa bukton, apan wala pa mapamatud-i nga mas kanunay mo-mature ang fistula, mao nga isipa kini nga katabang, dili garantiya.Itanung mu king siruhanu nung bage keka ing simpling pamipisil ning gamat. Ipakit ding malating pag-aral a malyari nang palaparan ing uyat king takiag, oneng e pa mapatunayan a mas malimit mag-mature ing fistula, kaya isipan meng katulung, e garantiya.

Look, listen, feel: your two-minute daily checkTingnan, pakinggan, damhin: ang iyong dalawang-minutong pagsusuri araw-arawTan-awa, paminawa, batia: ang imong duha-ka-minutong pagsusi adlaw-adlawLawan, pakiramdaman, damdaman: ing adwang minutung pamanyalikut aldo-aldo

You are the person who sees your access most often. A short daily check catches trouble early, often while it can still be fixed without losing the access.Ikaw ang pinakamadalas makakita ng iyong access. Ang maikling pagsusuri araw-araw ay nakakahuli ng problema nang maaga, madalas habang maaayos pa nang hindi nawawala ang access.Ikaw ang kanunay makakita sa imong access. Ang mubo nga pagsusi adlaw-adlaw makadakop sa problema og sayo, kasagaran samtang maayo pa nga dili mawala ang access.Ika ing pekamalimit makakit king access mu. Ing malagad a pamanyalikut aldo-aldo makakua problema kang aga, malimit kabang mapayapan pa nang e mawala ing access.

Three panels: looking at the arm for redness or swelling, listening to the whoosh with the ear close to the access, and feeling the buzz with fingertips.

Look for redness, swelling, or sores. Listen for the steady whoosh. Feel for the buzz. If anything changes, tell your dialysis team the same day.Tingnan kung may pamumula, pamamaga, o sugat. Pakinggan ang tuloy-tuloy na whoosh. Damhin ang buzz. Kapag may nagbago, sabihan ang dialysis team sa parehong araw.Tan-awa kung naay pagpula, paghubag, o samad. Paminawa ang padayong whoosh. Batia ang buzz. Kung naay nausab, sultihi ang dialysis team sa samang adlaw.Lawan nung atin pamula, pamalaga, o sugat. Pakiramdaman ing mipupugtung a whoosh. Damdaman ing buzz. Nung atin miyaliwa, sabyan me ing dialysis team king pareung aldo.

© renalcarematters.com

Poster of five warning signs at the access: bleeding that will not stop, lost buzz, cold or blue hand, fever or chills, and trouble breathing, each with a go-now arrow to the emergency room.

These five signs need emergency care now, not a calculator and not a wait until the next session.Ang limang palatandaang ito ay nangangailangan ng emergency care ngayon, hindi calculator at hindi paghihintay sa susunod na sesyon.Kining lima ka timailhan nanginahanglan og emergency care karon, dili calculator ug dili paghulat sa sunod nga sesyon.Deng limang tanda a iti kailangan dang emergency care ngeni, e calculator at e pamaglaus king susunod a sesyun.

© renalcarematters.com

Living safely with a catheter, and planning the way off itLigtas na pamumuhay kasama ang catheter, at plano para maalis itoLuwas nga pagkinabuhi uban ang catheter, ug plano aron makuha kiniLigtas a bie kayabe ing catheter, at planu para mekuang ya

A catheter can save a life when dialysis is needed quickly, and for some people it is the best long-term choice. Its weak spot is that the tube links the outside world to your bloodstream, so germs have a path in. Your nurses follow strict clean steps every time they open it. You help by keeping the dressing dry and closed, never letting anyone but trained staff open the caps, and reporting fever at once.Nakapagliligtas ng buhay ang catheter kapag kailangan agad ang dialysis, at para sa ilan ito ang pinakamainam na pangmatagalang pagpipilian. Ang kahinaan nito ay ikinokonekta ng tubo ang labas sa iyong dugo, kaya may daan ang mikrobyo. Mahigpit ang malinis na hakbang ng mga nurse tuwing bubuksan ito. Nakakatulong ka sa pagpapanatiling tuyo at sarado ng dressing, hindi pagpapabukas ng takip sa hindi sinanay na tao, at agad na pag-uulat ng lagnat.Makaluwas og kinabuhi ang catheter kung kinahanglan dayon ang dialysis, ug para sa uban kini ang labing maayo nga dugay nga kapilian. Ang kahuyang niini mao nga ang tubo nagkonektar sa gawas ngadto sa imong dugo, mao nga naay agianan ang mikrobyo. Estrikto ang limpyo nga lakang sa mga nurse matag abli niini. Makatabang ka pinaagi sa pagpabilin nga uga ug sirado ang dressing, dili pagpaabli sa takob sa dili batid, ug dayon pagreport sa hilanat.Makaligtas bie ing catheter nung kailangan agad ing dialysis, at para king nanu pekamayap yang pipiliyan king malawak a panaun. Ing kalatan na, ikonekta ning tubu ing lual king daya mu, kaya atin dalan ing mikrobyu. Mayigpit ing malinis a dalan dareng nurse balang buklat ra. Makasaup ka king pamanatili king dressing a mamaga at makasara, e pamipabuklat king takip king e sinanay, at agad a pamanyabi nung atin lagnat.

A dialysis nurse in mask and gloves scrubbing a catheter hub, beside a simple checklist of clean steps and a road sign pointing toward a fistula, graft, transplant, or peritoneal dialysis.

Clean hands, masks, scrubbed hubs, and a dry dressing protect the bloodstream. Alongside care, keep asking about the plan to remove the catheter when that is right for you.Malinis na kamay, mask, nilinis na hub, at tuyong dressing ang nagpoprotekta sa dugo. Kasabay ng pag-aalaga, patuloy na magtanong tungkol sa plano para alisin ang catheter kapag angkop.Limpyo nga kamot, mask, gilimpyohan nga hub, ug uga nga dressing ang mopanalipod sa dugo. Uban sa pag-atiman, padayon pagpangutana bahin sa plano sa pagkuha sa catheter kung angay.Malinis a gamat, mask, linisan a hub, at mamaga a dressing ing protektan king daya. Kayabe ning pamanalaga, mipupugtung kang magtanung tungkul king planu a kuanan ing catheter nung bage.

© renalcarematters.com

Ask at each review: Why do I still have the catheter? What is the next step to a fistula, graft, transplant, or peritoneal dialysis, and who is arranging it? If keeping the catheter is the right choice for you, ask what extra safety steps are in place.Itanong sa bawat pagsusuri: Bakit may catheter pa ako? Ano ang susunod na hakbang patungo sa fistula, graft, transplant, o peritoneal dialysis, at sino ang nag-aayos? Kung tamang piliin na manatili ang catheter, itanong ang dagdag na hakbang pangkaligtasan.Pangutana sa matag pagsusi: Nganong naa pa koy catheter? Unsa ang sunod nga lakang padulong sa fistula, graft, transplant, o peritoneal dialysis, ug kinsa ang nag-andam? Kung husto nga magpabilin ang catheter, pangutana sa dugang nga lakang sa kaluwasan.Itanung mu king balang pamanyalikut: Nokarin atin ku pang catheter? Nanu ing susunod a dalan pasibayu king fistula, graft, transplant, o peritoneal dialysis, at ninu ing mag-ayus? Nung tama a manatili ing catheter, itanung mu ing dagdag a dalan para king kaligtasan.

Fixing a failing access, and keeping the next option readyPag-aayos ng pumapalyang access, at paghahanda ng susunod na opsyonPag-ayo sa nagkapakyas nga access, ug pag-andam sa sunod nga kapilianPamag-ayus king mapalyang access, at pamaghanda king susunod a pipiliyan

When a narrowing is found and it is causing real problems, a specialist can often open it from inside with a small balloon (angioplasty), remove a clot (thrombectomy), or repair it surgically. Some balloons are coated with a drug that slows re-narrowing; in a large trial, they kept fistulas open longer than plain balloons, but the access can still need future procedures.Kapag may nakitang pagkitid na nagdudulot ng tunay na problema, kadalasan nabubuksan ito ng espesyalista mula sa loob gamit ang maliit na lobo (angioplasty), natatanggal ang namuong dugo (thrombectomy), o naaayos sa operasyon. May mga lobong may gamot na nagpapabagal ng muling pagkitid; sa malaking pag-aaral, mas matagal na bukas ang fistula kumpara sa karaniwang lobo, pero maaari pa ring kailanganin ang susunod na procedure.Kung naay nakit-ang pagkitid nga nagpahinabo og tinuod nga problema, kasagaran maablihan kini sa espesyalista gikan sa sulod gamit ang gamay nga lobo (angioplasty), makuha ang tuhop sa dugo (thrombectomy), o maayo sa operasyon. Ang uban nga lobo adunay tambal nga nagpahinay sa pagkitid pag-usab; sa dakong pagtuon, mas dugay nga bukas ang fistula kumpara sa naandang lobo, apan mahimong kinahanglan gihapon ang sunod nga procedure.Nung atin akit a pamikitid a magdulut ning tune a problema, kalimitan buklatan ne ning espesyalista ibat king lub king malating lobu (angioplasty), kuanan ing memu a daya (thrombectomy), o ayusan king operasyun. Atin lobu a atin gamut a mamabagal king pamikitid pasibayu; king maragul a pag-aral, mas matagal a makabuklat ing fistula kesa king karaniwang lobu, oneng malyari pa ring kailangan ing susunod a procedure.

A winding road through five signposts: plan early, protect every vessel, recognize trouble, rescue wisely, preserve the next option, with a fistula, a graft, peritoneal dialysis, and a transplant as places along the way.

A lifetime plan is a road with stops, not one single access. Protecting veins today keeps tomorrow's options open.Ang plano habambuhay ay daan na may mga hintuan, hindi iisang access. Ang pagprotekta sa ugat ngayon ay nagpapanatiling bukas ng opsyon bukas.Ang plano sa tibuok kinabuhi usa ka dalan nga adunay mga hunonganan, dili usa lang ka access. Ang pagpanalipod sa ugat karon nagpabilin nga bukas sa kapilian ugma.Ing planu king bie metung yang dalan a atin pamikakalan, e metung mung access. Ing pamanyalikut king uyat ngeni ilili nang makabuklat ing pipiliyan bukas.

© renalcarematters.com

Every procedure is also a decision about the future. A stent placed today may affect where a new access can go later. If your access fails again and again, ask for a team review that includes your nephrologist, surgeon, and interventional specialist, so the next step protects your remaining options.Bawat procedure ay desisyon din tungkol sa hinaharap. Ang stent na inilagay ngayon ay maaaring makaapekto kung saan mailalagay ang bagong access. Kung paulit-ulit na pumapalya ang access, humiling ng pagsusuri ng team na kasama ang nephrologist, siruhano, at interventional specialist, para maprotektahan ng susunod na hakbang ang natitirang opsyon.Matag procedure usa usab ka desisyon bahin sa umaabot. Ang stent nga gibutang karon mahimong makaapekto kung asa ibutang ang bag-ong access. Kung balik-balik nga mapakyas ang access, pangayo og pagsusi sa team nga naglakip sa nephrologist, siruhano, ug interventional specialist, aron ang sunod nga lakang mopanalipod sa nahabilin nga kapilian.Balang procedure desisyun ya mu rin tungkul king darating. Ing stent a ibili ngeni malyaring makaapektu nung nu ibili ing bayung access. Nung paulit-ulit a mapalya ing access, ali kang pamanyalikut ning team a kayabe ing nephrologist, siruhanu, at interventional specialist, para protektan ning susunod a dalan ing mekabiling pipiliyan.

🔬

Things that have not been shown to helpMga bagay na hindi napatunayang nakakatulongMga butang nga wala mapamatud-ang makatabangBage a e mapatunayang makasaup

In a large trial, fish oil and aspirin did not stop new fistulas from failing. A 2026 trial of far-infrared heat therapy did not reduce procedures. Spend your energy on vein protection, daily checks, and early reporting.Sa malaking pag-aaral, hindi napigilan ng fish oil at aspirin ang pagpalya ng bagong fistula. Sa isang pag-aaral noong 2026, hindi nabawasan ng far-infrared heat therapy ang mga procedure. Ituon ang lakas sa pagprotekta ng ugat, araw-araw na pagsusuri, at maagang pag-uulat.Sa dakong pagtuon, wala mapugngi sa fish oil ug aspirin ang pagkapakyas sa bag-ong fistula. Sa usa ka pagtuon sa 2026, wala makunhuri sa far-infrared heat therapy ang mga procedure. Ibutang ang kusog sa pagpanalipod sa ugat, adlaw-adlaw nga pagsusi, ug sayo nga pagreport.King maragul a pag-aral, e apigilan ning fish oil at aspirin ing pamalya ning bayung fistula. King metung a pag-aral king 2026, e akunian ning far-infrared heat therapy ding procedure. Itutuk me ing sikan mu king pamanyalikut king uyat, aldo-aldong pamanyalikut, at agad a pamanyabi.

Carry your access story with youDalhin ang kuwento ng iyong accessDad-a ang istorya sa imong accessDarwan me ing kwentu ning access mu

Doctors in a new hospital often do not know which veins were used, which catheters came before, or what your plan is. A one-page access passport answers those questions in seconds and helps protect your next option.Madalas hindi alam ng doktor sa bagong ospital kung aling ugat ang nagamit, aling catheter ang nauna, o ano ang plano mo. Ang isang-pahinang access passport ay sumasagot dito sa ilang segundo at tumutulong protektahan ang susunod mong opsyon.Kasagaran wala mahibal-i sa doktor sa bag-ong ospital kung asa nga ugat ang nagamit, asa nga catheter ang nauna, o unsa ang imong plano. Ang usa-ka-panid nga access passport motubag niini sa pila ka segundo ug motabang pagpanalipod sa imong sunod nga kapilian.Malimit e balu ning doktor king bayung ospital nung nanung uyat ing megamit, nanung catheter ing mekaunang, o nanu ing planu mu. Ing metung-bulung a access passport sasagut kareti king pilan a segundu at tutulung a protektan ing susunod mung pipiliyan.

Fill this in on screen, then print it. Nothing you type is saved or sent anywhere; it disappears when you close the page.Punan ito sa screen, saka i-print. Walang tinatype mo ang naiimbak o naipapadala; nawawala ito kapag isinara ang pahina.Pun-a kini sa screen, unya i-print. Walay imong gi-type ang matipigan o mapadala; mawala kini kung sirad-an ang panid.Punan me iti king screen, kaybat i-print. Alang tinype mu a maimbak o mipadala; mawala ya nung isara me ing bulung.

Practical notes for Filipino familiesPraktikal na paalala para sa pamilyang PilipinoPraktikal nga pahinumdom para sa pamilyang PilipinoPraktikal a paalala para king pamilyang Pilipinu

Common questionsMga karaniwang tanongKasagarang pangutanaKaraniwan a kutang

Will my fistula last forever?Tatagal ba habambuhay ang fistula ko?Molungtad ba hangtod sa kahangtoran ang akong fistula?Tumagal ya ba angga king kamatayan ing fistula ku?
Some fistulas last many years, but no one can promise that. That is why the goal is a lifetime plan: protect this access, know your backup, and keep future options open.May fistula na tumatagal nang maraming taon, pero walang makapangangako niyan. Kaya ang layunin ay isang plano habambuhay: protektahan ang access na ito, alamin ang backup, at panatilihing bukas ang mga susunod na opsyon.Ang ubang fistula molungtad og daghang tuig, apan walay makasaad niana. Mao nga ang tumong usa ka plano sa tibuok kinabuhi: panalipdi kini nga access, hibal-i ang backup, ug ipabilin nga bukas ang sunod nga kapilian.Atin fistula a tumagal dakal a banwa, oneng alang makapangaku kaniti. Kaya ing layunin metung yang planu king bie: protektan ing access a iti, abalu me ing backup, at panatilian meng makabuklat ing susunod a pipiliyan.
Is it my fault that my access keeps clotting?Kasalanan ko ba na paulit-ulit namumuo ang dugo sa access ko?Akong sala ba nga balik-balik motuhop ang dugo sa akong access?Kasalanan ku ba a paulit-ulit a mamuu ing daya king access ku?
Usually not. Narrowing is mostly the vein's own reaction to high flow. What helps most is noticing changes early and reporting them.Kadalasan hindi. Ang pagkitid ay kadalasang reaksyon ng ugat sa malakas na daloy. Ang pinakamakakatulong ay ang maagang pagpansin at pag-uulat ng pagbabago.Kasagaran dili. Ang pagkitid kasagaran reaksyon sa ugat sa kusog nga dagan. Ang labing makatabang mao ang sayo nga pagmatikod ug pagreport sa kausaban.Kalimitan ali. Ing pamikitid kalimitan reaksyun ning uyat king masikan a agus. Ing pekamakasaup ing agang pamamansin at pamanyabi ning pamaliwa.
Can I lift things or exercise with my fistula arm?Maaari ba akong magbuhat o mag-ehersisyo gamit ang brasong may fistula?Mahimo ba ko mobuhat o mo-ehersisyo gamit ang bukton nga naay fistula?Malyari ku bang mamuat o mag-ehersisyu king takiag a atin fistula?
Gentle everyday use and exercise are usually fine and are encouraged. Avoid heavy loads pressing on the access, tight straps, and sleeping on it. Ask your team about your specific limits.Karaniwang ayos at hinihikayat ang marahang paggamit araw-araw at ehersisyo. Iwasan ang mabigat na dumidiin sa access, masisikip na strap, at pagtulog dito. Itanong sa team ang tiyak mong limitasyon.Kasagaran okay ug giawhag ang hinay nga paggamit adlaw-adlaw ug ehersisyo. Likayi ang bug-at nga mopislit sa access, hugot nga strap, ug pagkatulog niini. Pangutana sa team ang imong piho nga limitasyon.Karaniwan mayap at aliwa ing malumanay a pamamagamit aldo-aldo at ehersisyu. Pangilagan ing mabayat a mipindut king access, masikip a strap, at pamanudtud kaniti. Itanung me king team ing tiyak mung limitasyun.
Why do they keep checking flow or doing ultrasounds?Bakit paulit-ulit nilang sinusuri ang daloy o nag-uultrasound?Nganong balik-balik nilang susihon ang dagan o mag-ultrasound?Nokarin paulit-ulit dang lalawan ing agus o mag-ultrasound?
These tests help explain a problem the team has already noticed. A single number alone should not trigger a procedure; your team looks at the whole picture, including how dialysis is going.Tinutulungan ng mga test na ito na ipaliwanag ang problemang napansin na ng team. Hindi dapat magdulot ng procedure ang iisang numero lang; tinitingnan ng team ang buong larawan, kasama kung paano ang dialysis.Kini nga mga test makatabang pagpatin-aw sa problema nga namatikdan na sa team. Dili angay nga usa ra ka numero ang mopahinabo og procedure; tan-awon sa team ang tibuok hulagway, lakip kung unsa ang dagan sa dialysis.Tutulung deng test a iti a ipaliwanag ing problema a apansin na ning team. E dapat metung mung numeru ing magdulut ning procedure; lalawan ning team ing buung larawan, kayabe nung makananu ing dialysis.

What the evidence shows, and how sure we are

This guide asks one question: how can a multidisciplinary team maximize usable dialysis access and minimize catheter exposure, infection, repeated procedures, pain, and loss of future options across a person’s whole treatment journey? It is a focused synthesis of guidelines and trials verified against PubMed on November 11, 2026, not a systematic review. Every number below carries its population, endpoint, and horizon, because the same percentage means very different things across those three.

Guideline Graded guideline statement or practice point (grade quoted only where checked)
Randomized Randomized trial result, for that trial’s population and endpoint
Observational Observational association; confounding not excluded
Review Narrative review or implementation resource
Emerging Emerging: single trial, industry-funded, or not yet available locally
Operational tool Proposed operational tool; arithmetic, not a validated predictor
QuestionBest current answerLabel
Fistula for everyone?No. Kidney Disease Outcomes Quality Initiative (KDOQI) 2019 and UK Kidney Association (UKKA) 2025 replace “fistula first” with an individualized End-Stage Kidney Disease (ESKD) Life-Plan chosen with the patient.1,2Guideline
When to start planning?Kidney Disease: Improving Global Outcomes (KDIGO) 2024 practice point: a 2-year kidney failure risk above 40% can inform modality education and kidney replacement therapy (KRT) preparation, including access planning, alongside estimated glomerular filtration rate (eGFR) and clinical judgment.3Guideline
Instrument surveillance of a well-functioning access?KDOQI does not support routine surveillance or preemptive angioplasty of an asymptomatic stenosis; act on clinical indicators.1Guideline
Drug-coated balloon (DCB) for fistula stenosis?36-month target lesion primary patency (TLPP) 43.1% versus 28.6% with plain angioplasty; 5-year mortality not different (59.0% versus 53.5% alive, p = 0.51).4,5Randomized
Taurolidine/heparin catheter lock?Catheter-related bloodstream infection (CRBSI) 0.13 versus 0.46 per 1,000 catheter-days; hazard ratio (HR) 0.29, 95% confidence interval (CI) 0.14–0.62.6Randomized
Anticoagulation after thrombectomy?Apixaban 2.5 mg twice daily for 3 months: recurrent thrombosis 24.0% versus 40.8% (HR 0.52); minor bleeding 22.6% versus 7.5%. Open-label, single-country trial.7Randomized Emerging
Fish oil or aspirin to protect a new fistula?No reduction in 12-month fistula failure (47% versus 47%).11Randomized
Bioengineered vessel instead of a fistula?Higher 6-month functional patency (81.3% versus 66.4%) but more interventions; manufacturer-funded, unmasked, United States only.9Randomized Emerging

Formal grades are quoted only where the exact statement was checked. Where a guideline offers an ungraded practice point, it is labeled as such. Abstract-level extraction is marked in the text; treat novel therapeutic claims as provisional until the full text and supplements are reviewed.

Why the lifeline fails: from wall shear stress to the whole patient

Normal function first. A forearm cephalic vein carries perhaps tens of milliliters per minute at low pressure. Joining it to an artery abruptly raises flow roughly tenfold or more. A healthy vein answers with outward remodeling: endothelial cells sense the rise in laminar wall shear stress, release nitric oxide, and the vessel dilates and thickens so that shear returns toward its set point. Maturation is that adaptation succeeding.

What breaks. Where flow is disturbed rather than laminar, typically the juxta-anastomotic “swing segment,” the cephalic arch, and graft-vein anastomoses, low and oscillating shear switches the endothelium toward a pro-inflammatory phenotype. Smooth muscle cells and myofibroblasts migrate into the intima and proliferate: neointimal hyperplasia. If outward remodeling fails at the same time, the lumen narrows, flow falls, and the access either never matures or later thromboses. Uremia amplifies each step through oxidative stress, endothelial dysfunction, and vascular calcification linked to chronic kidney disease–mineral and bone disorder (CKD-MBD); diabetes and pre-existing venous injury from cannulas and central lines add to it. Peripheral stenosis is therefore mostly biology, not blame.

Mechanism schematic: arm with fistula, magnified juxta-anastomotic segment showing disturbed flow, endothelial activation, smooth muscle migration, neointimal hyperplasia, and failed outward remodeling.

Disturbed flow near the anastomosis drives neointimal hyperplasia; if outward remodeling fails, the lumen narrows and the access fails to mature or thromboses.

AVF
Arteriovenous fistula
NO
Nitric oxide
SMC
Smooth muscle cell
WSS
Wall shear stress

© renalcarematters.com

Other failure pathways need different responses. Central venous stenosis follows catheters and cardiac device leads and can doom every ipsilateral access; cannulation injury causes hematoma, infiltration, and aneurysm; infection follows breaches in asepsis, with catheters carrying the highest risk; hand ischemia (often called steal) reflects arterial inflow limits; and very high access flow (Qa) adds a fixed left-to-right shunt that raises cardiac output (CO). The access thus links the vascular, cardiac, inflammatory, and mineral-bone systems, which is why repeated access failure belongs in a multidisciplinary review, not a procedure queue.

Plan the next decade before the next procedure

KDOQI 2019 centers access on an ESKD Life-Plan: the patient’s kidney replacement goals and preferences, then the access that fits them now, the contingency if it fails, and the succession of options that follows.1 UKKA 2025 frames access selection as an informed choice rather than a rule, while keeping the well-functioning fistula as the access with the most durable outcomes when it can be achieved.2

Living access passport: what every chart should hold
1
Goals. Hemodialysis, peritoneal dialysis, transplant listing, conservative kidney management, or a time-limited trial; expected horizon.
2
Anatomy. Dominant arm, vein mapping results, arterial inflow, and central venous history (catheters, peripherally inserted central catheters, cardiac device leads).
3
History. Every prior access with creation date, first use, interventions, and reason for abandonment.
4
Now and next. Current access, owner, next review date, contingency access, and the next two options in order.
5
Overrides. Any decision that departs from the default pathway, with its reason documented, so a planning prompt never becomes a mandate.

Timing. The KDIGO 2024 practice point that a 2-year Kidney Failure Risk Equation (KFRE) risk above 40% can prompt KRT preparation is a timing aid; it is not an access-patency predictor and does not apply once maintenance dialysis has begun.3 Regional calibration of the equation matters for Southeast Asian populations. Vein preservation (no peripherally inserted central catheter in a patient likely to need hemodialysis, venipuncture on the dorsal hand or non-access arm) is the cheapest intervention in this guide.

Roadmap infographic with five stations: plan early, protect every vessel, recognize trouble, rescue wisely, preserve the next option, and branches to fistula, graft, peritoneal dialysis, and transplant.

The lifetime strategy is a succession plan: each access decision is judged by what it leaves available next.

AVF
Arteriovenous fistula
AVG
Arteriovenous graft
PD
Peritoneal dialysis

© renalcarematters.com

Choose with the person: trade-offs, not a ranking

No numerical ranking captures the trade-offs, so present them as dimensions the patient weighs. Device-specific claims (early-cannulation grafts, endovascular fistula systems, bioengineered vessels) should be sourced before detailed counseling and checked for local availability.

DimensionArteriovenous fistula (AVF)Arteriovenous graft (AVG)Central venous catheter (CVC)
Time to usableWeeks to months; may need assisted maturationUsually weeks; early-cannulation grafts soonerImmediate
Initial failureHighest; maturation failure commonLower primary failureDysfunction rather than maturation
Long-term maintenanceFewest interventions once matureMore stenosis and thrombosisLock, dressing, exchange burden
InfectionLowestIntermediateHighest
Effect on future optionsUses a vein segmentUses outflow veinCentral venous stenosis risk
Patient factorsNeedle fear, appearance, steal riskSwelling early, needling soonerNo needles; bathing limits

Endovascular fistula (eAVF). A 2026 meta-analysis of 28 studies (8 comparative, none of them large randomized trials) pooled technical success of 97% and maturation of 77%, with no significant difference from surgical fistulas in maturation or primary patency, numerically more reinterventions, and fewer complications, amid substantial heterogeneity.18 Observational It is a specialist option for suitable anatomy, not a replacement for surgical expertise.

Acellular tissue-engineered vessel (ATEV). In the phase 3 V007 trial (242 catheter-dependent adults, 31 United States centers, unmasked), ATEV achieved a global relative patency of 1.17 (95% CI 1.04–1.31) versus fistula, with 6-month functional patency 81.3% versus 66.4% and 12-month secondary patency 67.5% versus 62.2%; ATEV required more interventions, infection rates were similar, and the trial was manufacturer-funded.9 Randomized Emerging Its regulatory status for dialysis access and availability in the Philippines must be verified independently; the trial does not establish lifetime durability.

Three-column comparison of fistula, graft, and catheter with time-to-use bars and icons for infection, interventions, and future options.

Each access trades speed, durability, intervention burden, and infection risk differently.

AVF
Arteriovenous fistula
AVG
Arteriovenous graft
CVC
Central venous catheter

© renalcarematters.com

From creation to dependable use

Separate anatomical maturation (diameter, flow, depth) from clinical usability (sustained two-needle dialysis at the prescribed blood pump flow). A calendar interval or a vessel diameter alone should never authorize first cannulation; the decision belongs to an experienced cannulator after examination and, where available, ultrasound.

In the Hemodialysis Fistula Maturation Study (602 participants, prospective, multicenter), postoperative ultrasound blood flow, diameter, and depth each independently predicted clinical maturation; cross-validated area under the curve for unassisted maturation was 0.69, 0.74, and 0.79 at 1 day, 2 weeks, and 6 weeks.10 Observational That is moderate discrimination with internal cross-validation only, so it supports earlier referral of a lagging fistula, not a deterministic “ready to needle” rule. No calculator is offered here until the full model is externally validated.

Postoperative timeline: each step has an owner and a date
1
Days 1–14. Wound check, thrill present, hand perfusion and sensation documented.
2
About 4–6 weeks. Clinical examination by the access team; ultrasound where available. A fistula that is not progressing is referred now, not at month four.
3
First cannulation. Planned, mapped, small-gauge needles, experienced cannulator, reduced blood pump flow; record the reason for any delay.
4
Sustained use. Date of reliable two-needle dialysis recorded; catheter removal planned with a named owner.

Adjuncts. An 8-week preoperative isometric hand-exercise program in 54 Thai patients increased cephalic vein diameter and radiocephalic creation (93.8% versus 58.3%) without changing 12-week maturation.17 Randomized Apixaban after fistula creation in a 92-patient two-center trial lowered early anastomotic stenosis (9.1% versus 29.2%), but thrombosis (6.8% versus 18.8%, p = 0.09) and primary patency were not significantly different and 22.7% had bleeding episodes; this suggests a hypothesis, not a routine prescription.8 Randomized Emerging Fish oil and aspirin did not reduce 12-month fistula failure in FAVOURED (fish oil 128/270 versus 125/266; adjusted relative risk 1.03, 95% CI 0.86–1.23).11 Randomized

Horizontal timeline from surgery to dependable two-needle use, with checkpoints, owners, and an ultrasound inset.

Maturation is judged clinically at defined checkpoints; diameter or calendar time alone does not authorize cannulation.

US
Ultrasound

© renalcarematters.com

Every cannulation is an access-preservation event

Two needles, about 150 times a year, make cannulation the most frequent procedure an access undergoes. Infiltration can cost a new fistula; repeated area puncture produces aneurysms; poor asepsis seeds infection. A nurse-facing workflow treats each session as assess, match, place, protect, and escalate.

TechniqueWhat the evidence suggestsMain caution
Rope-ladderDefault for most fistulas and all grafts in KDOQI 2019; spreads sites along the vessel.1Needs adequate cannulation length
ButtonholeA meta-analysis of 15 small trials reported fewer aneurysms, stenoses, thromboses, and hematomas than rope-ladder, with a nonsignificant trend toward more infection.19Infection; reserve for selected patients with strict tract care
Area punctureConvenient but associated with aneurysm formationDiscourage

Practical anchors: assess before every session (look, listen, feel, arm elevation, augmentation); match difficult accesses to experienced cannulators; use ultrasound guidance for new, deep, or tortuous vessels where available; map sites; address needle pain, since fear of cannulation drives catheter preference; respond to infiltration by stopping, applying pressure, resting the segment, and documenting.

Three fistula diagrams comparing rope-ladder site rotation, a single buttonhole tract, and clustered area puncture with aneurysm formation.

Rope-ladder spreads punctures, buttonhole reuses a tract, and area puncture concentrates injury and promotes aneurysm.

AVF
Arteriovenous fistula

© renalcarematters.com

Detect dysfunction before dialysis is lost

Monitoring is the clinical examination and the dialysis session itself: physical examination, difficult cannulation, prolonged bleeding after needle removal, rising venous pressure, falling achievable blood pump flow, unexplained fall in delivered dose, recirculation, and arm swelling. Surveillance is periodic instrument measurement, such as access flow by dilution or duplex. KDOQI 2019 does not support adding routine surveillance to clinical monitoring to improve patency, nor preemptive angioplasty of a stenosis without clinical indicators.1 Guideline

Keep three steps separate: a clinical concern, a confirmatory investigation (duplex or angiography) that shows a lesion and its hemodynamic significance, and a treatment decision that weighs that lesion against the access history and patient goals. A radiologic percentage stenosis alone is not an angioplasty trigger, and a single flow or pressure value should never auto-generate a procedure order. Trends matter more than snapshots, and measurement conditions must match before two values are compared.

Clinical algorithm: clinical indicators lead to confirmatory imaging, then a multidisciplinary treatment decision; an isolated abnormal number loops back to repeat measurement under comparable conditions.

Concern, confirmation, and decision are three separate steps; an isolated number loops back to repeat measurement.

Qa
Access blood flow
Qb
Blood pump flow
Kt/V
Dialysis dose index

© renalcarematters.com

Rescue the access and preserve the next option

Drug-coated balloons. IN.PACT AV Access randomized 330 participants at 29 international sites with dysfunctional native upper-extremity fistulas, after successful high-pressure angioplasty, to a paclitaxel DCB (170) or plain percutaneous transluminal angioplasty (PTA, 160). Through 36 months, TLPP was 43.1% versus 28.6% and access circuit primary patency (ACPP) 26.4% versus 16.6% (both log-rank p < 0.001); access circuit thrombosis was 8.2% versus 18.3%.4 Randomized The 2026 update from the same trial (not an independent replication) reported consistent TLPP direction across lesion and fistula subsets and 60-month freedom from death of 59.0% versus 53.5% (p = 0.51), easing the paclitaxel mortality concern without proving absence of harm.5 These are Kaplan–Meier estimates for one target lesion, not whole-access survival; do not convert them into a conventional number needed to treat (NNT).

A 2026 Chinese multicenter trial in 219 patients with failing fistulas or grafts found a predilation-free scoring paclitaxel-coated balloon improved 6-month TLPP (78.9% versus 57.3%; absolute difference 21.2 percentage points), but the 12-month difference was not significant (63.5% versus 52.4%).15 Randomized Emerging

Thrombosis. After successful endovascular thrombectomy in 186 Taiwanese patients, apixaban 2.5 mg twice daily for 3 months reduced 3-month recurrent access thrombosis (24.0% versus 40.8%; HR 0.52, 95% CI 0.31–0.88) and primary patency failure (32.2% versus 49.5%), with similar major bleeding and death but more minor bleeding (22.6% versus 7.5%).7 Randomized Emerging In crude terms that is about 1 recurrence prevented per 6 patients treated and 1 extra minor bleed per 7, within an open-label design. It informs a case-by-case discussion after thrombectomy; it does not support routine anticoagulation of every new fistula or catheter. No prescribing tool is offered here.

Interventions that did not help. In a Danish multicenter trial of 115 patients with well-functioning fistulas, far-infrared therapy at every session for 1 year did not reduce the proportion needing an intervention, thrombosis, or flow decline.16 Randomized

Succession. Stent-grafts can rescue resistant or recurrent lesions but consume outflow vein and can complicate future surgery; record that trade-off in the passport. A patient with repeated failures needs a multidisciplinary review of the whole circuit, central veins, and goals, with any local threshold for that review cited and documented before it is applied.

Algorithm for a dysfunctional or thrombosed access: urgent assessment, imaging, lesion-focused treatment options, and a multidisciplinary review loop for repeated failure that protects future access sites.

Lesion-focused rescue is chosen with an eye on what it leaves for the next access.

DCB
Drug-coated balloon
PTA
Percutaneous transluminal angioplasty
MDT
Multidisciplinary team
PD
Peritoneal dialysis

© renalcarematters.com

Make catheter days safer while reducing avoidable dependence

Basic asepsis first. The Centers for Disease Control and Prevention (CDC) Core Interventions combine monthly bloodstream infection (BSI) surveillance with feedback, hand hygiene and catheter-care audits, staff competency, patient education, catheter reduction, chlorhexidine skin antisepsis, hub scrubbing, and exit-site care.14 Review Antimicrobial locks supplement these steps; they do not replace them.

Locks. LOCK IT-100 randomized adults dialyzing through catheters at 70 United States sites to taurolidine 13.5 mg/mL plus heparin 1,000 units/mL or heparin 1,000 units/mL; it stopped early for efficacy. In the full analysis population (795), CRBSI occurred in 9 of 397 versus 32 of 398 participants, 0.13 versus 0.46 per 1,000 catheter-days (HR 0.29, 95% CI 0.14–0.62), with no difference in catheter removal or loss of patency and comparable safety.6 Randomized The 71% figure is a relative hazard reduction; the absolute rate difference is 0.33 per 1,000 catheter-days, so at 10,000 catheter-days the trial rates imply about 4.6 versus 1.3 infections. Industry funding, early stopping, and formulation-specific results argue against assuming a class effect for every antimicrobial lock. In a 2026 Thai trial of 204 patients, 5% trisodium citrate and heparin 1,000 units/mL had similar catheter dysfunction, CRBSI, bleeding, and mortality at 180 days.20 Randomized

Exposure. Track catheter-present days, the reason a catheter remains, and the next step with a named owner. A retained catheter can be the right choice for limited life expectancy, exhausted anatomy, or patient preference; then document the reason and the safety plan rather than counting it as a failure.

Catheter care bundle infographic: hand hygiene, mask, hub scrub, chlorhexidine exit-site care, lock, dressing, surveillance board, and an exit-plan arrow toward permanent access.

Infection prevention is a bundle; antimicrobial locks add to it, and every catheter needs a documented reason and plan.

CRBSI
Catheter-related bloodstream infection
CVC
Central venous catheter

© renalcarematters.com

High-flow access and the heart

An arteriovenous access is a permanent low-resistance shunt. Most patients tolerate it, but in some, particularly with upper-arm fistulas and pre-existing cardiac disease, a high Qa raises CO enough to contribute to high-output heart failure. In 96 Italian patients, upper-arm fistulas had higher mean Qa (1.58 versus 0.95 L/min) and Qa of 2.0 L/min or more identified the 10 patients classified as having high-output failure with high accuracy (sensitivity 89%, specificity 100%) in that same small cohort.12 Observational That threshold is a prompt for assessment (symptoms, volume status, echocardiography, measurement conditions), not a diagnosis or an automatic indication for flow reduction. Keep access flow (Qa) distinct from the prescribed extracorporeal blood pump flow (Qb).

Monoline organ sigil connecting an arm fistula, the heart, the lungs, and the kidney with flow arrows illustrating shunt flow, cardiac output, and congestion.

A high-flow access adds to the work of the heart; assessment weighs symptoms, volume, and cardiac function together.

Qa
Access blood flow
CO
Cardiac output

© renalcarematters.com

What is new, and what is ready

DevelopmentEvidence (date)Ready for routine use?
Individualized Life-Plan replaces “fistula first”KDOQI 2019 (published 2020); UKKA, August 20251,2Yes: practice framework
Paclitaxel DCB for fistula stenosis36-month randomized controlled trial (RCT, 2023); 5-year mortality update, August 20264,5Option where available and funded; lesion-specific
Taurolidine/heparin lockPhase 3 RCT (2023)6Depends on local registration, cost, and protocol review
Apixaban after thrombectomyOpen-label RCT, online November 2024 (issue 2025)7Case-by-case; awaits replication
Bioengineered vessel (ATEV)Phase 3 RCT, August 20269Not available locally; verify regulatory status
Endovascular fistulaMeta-analysis, March 202618Specialist centers; selected anatomy
Exercise for accessSmall RCTs, 2026; vessel diameter surrogates17,21Low-risk adjunct; outcome benefit unproven
Far-infrared therapyRCT, 2026; no benefit16No

A 2026 single-center trial of 100 patients reported that a 12-week exercise program increased access vessel diameter by 0.9 versus 0.1 mm and improved walking distance and quality-of-life scores.21 Randomized Vessel diameter is a surrogate; the trial did not show fewer access failures. A 2026 narrative review in Clinical Kidney Journal argues that outcomes depend on a coherent, longitudinal, nephrologist-coordinated approach rather than any single intervention, a view this guide shares.13 Review

Dated evidence timeline from 2017 to 2026 with color-coded markers for guidelines, randomized trials, and emerging technology, and a readiness meter beside each.

Publication is not the same as validation, regulatory approval, or local availability.

© renalcarematters.com

Measure what matters, with honest denominators

A unit cannot improve what it does not count, and it cannot compare what it counts differently. Report each metric separately with its definition, denominator, and time origin; avoid a composite “lifeline health” score that hides trade-offs.

MetricDefinition and denominator
Catheter exposureCatheter-present days divided by observed patient-days; union of overlapping intervals; state whether present or actually used
Time to sustained useCreation date to first date of reliable two-needle dialysis
Primary, assisted, secondary patencyKaplan–Meier from creation or from intervention; state the time origin and censoring rules
Access-related infectionEvents per 1,000 catheter- or access-days with exact 95% CI; keep CRBSI, all BSI, and surveillance definitions distinct
Intervention burdenMaturation and maintenance procedures separately, per access-year
Patient experienceCannulation pain, missed sessions, delay to specialist review

Implementation notes for Philippine units

The trials above were conducted in the United States, Europe, East Asia, and Egypt. Their device availability, costs, and outcomes should not be presented as Philippine facts. Points to configure locally:

What we still do not know, and tools we deliberately did not build

Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

ACPP
Access circuit primary patency.Access circuit primary patency.Access circuit primary patency.Access circuit primary patency.
ATEV
Acellular tissue-engineered vessel: a lab-grown, cell-free blood vessel used as an access.Acellular tissue-engineered vessel: a lab-grown, cell-free blood vessel used as an access.Acellular tissue-engineered vessel: a lab-grown, cell-free blood vessel used as an access.Acellular tissue-engineered vessel: a lab-grown, cell-free blood vessel used as an access.
AVF
Arteriovenous fistula: an artery joined directly to a vein.Arteriovenous fistula: an artery joined directly to a vein.Arteriovenous fistula: an artery joined directly to a vein.Arteriovenous fistula: an artery joined directly to a vein.
AVG
Arteriovenous graft: a tube joining an artery to a vein.Arteriovenous graft: a tube joining an artery to a vein.Arteriovenous graft: a tube joining an artery to a vein.Arteriovenous graft: a tube joining an artery to a vein.
BSI
Bloodstream infection.Bloodstream infection.Bloodstream infection.Bloodstream infection.
CDC
Centers for Disease Control and Prevention (United States).Centers for Disease Control and Prevention (United States).Centers for Disease Control and Prevention (United States).Centers for Disease Control and Prevention (United States).
CKD
Chronic kidney disease.Chronic kidney disease.Chronic kidney disease.Chronic kidney disease.
CKD-MBD
Chronic kidney disease–mineral and bone disorder.Chronic kidney disease–mineral and bone disorder.Chronic kidney disease–mineral and bone disorder.Chronic kidney disease–mineral and bone disorder.
CO
Cardiac output: blood pumped by the heart per minute.Cardiac output: blood pumped by the heart per minute.Cardiac output: blood pumped by the heart per minute.Cardiac output: blood pumped by the heart per minute.
CRBSI
Catheter-related bloodstream infection.Catheter-related bloodstream infection.Catheter-related bloodstream infection.Catheter-related bloodstream infection.
CVC
Central venous catheter.Central venous catheter.Central venous catheter.Central venous catheter.
DCB
Drug-coated balloon.Drug-coated balloon.Drug-coated balloon.Drug-coated balloon.
eAVF
Endovascular arteriovenous fistula, made through needles and catheters instead of open surgery.Endovascular arteriovenous fistula, made through needles and catheters instead of open surgery.Endovascular arteriovenous fistula, made through needles and catheters instead of open surgery.Endovascular arteriovenous fistula, made through needles and catheters instead of open surgery.
eGFR
Estimated glomerular filtration rate.Estimated glomerular filtration rate.Estimated glomerular filtration rate.Estimated glomerular filtration rate.
ESKD
End-stage kidney disease.End-stage kidney disease.End-stage kidney disease.End-stage kidney disease.
FDA
Food and Drug Administration.Food and Drug Administration.Food and Drug Administration.Food and Drug Administration.
HMO
Health maintenance organization.Health maintenance organization.Health maintenance organization.Health maintenance organization.
HR
Hazard ratio.Hazard ratio.Hazard ratio.Hazard ratio.
KDIGO
Kidney Disease: Improving Global Outcomes.Kidney Disease: Improving Global Outcomes.Kidney Disease: Improving Global Outcomes.Kidney Disease: Improving Global Outcomes.
KDOQI
Kidney Disease Outcomes Quality Initiative (National Kidney Foundation).Kidney Disease Outcomes Quality Initiative (National Kidney Foundation).Kidney Disease Outcomes Quality Initiative (National Kidney Foundation).Kidney Disease Outcomes Quality Initiative (National Kidney Foundation).
KFRE
Kidney Failure Risk Equation.Kidney Failure Risk Equation.Kidney Failure Risk Equation.Kidney Failure Risk Equation.
KRT
Kidney replacement therapy: dialysis or transplant.Kidney replacement therapy: dialysis or transplant.Kidney replacement therapy: dialysis or transplant.Kidney replacement therapy: dialysis or transplant.
MDT
Multidisciplinary team.Multidisciplinary team.Multidisciplinary team.Multidisciplinary team.
NNT
Number needed to treat.Number needed to treat.Number needed to treat.Number needed to treat.
PD
Peritoneal dialysis.Peritoneal dialysis.Peritoneal dialysis.Peritoneal dialysis.
PICC
Peripherally inserted central catheter.Peripherally inserted central catheter.Peripherally inserted central catheter.Peripherally inserted central catheter.
PTA
Percutaneous transluminal angioplasty.Percutaneous transluminal angioplasty.Percutaneous transluminal angioplasty.Percutaneous transluminal angioplasty.
Qa
Access blood flow, in mL/min.Access blood flow, in mL/min.Access blood flow, in mL/min.Access blood flow, in mL/min.
Qb
Blood pump flow set on the dialysis machine.Blood pump flow set on the dialysis machine.Blood pump flow set on the dialysis machine.Blood pump flow set on the dialysis machine.
QAPI
Quality assessment and performance improvement.Quality assessment and performance improvement.Quality assessment and performance improvement.Quality assessment and performance improvement.
RCT
Randomized controlled trial.Randomized controlled trial.Randomized controlled trial.Randomized controlled trial.
TLPP
Target lesion primary patency.Target lesion primary patency.Target lesion primary patency.Target lesion primary patency.
UKKA
UK Kidney Association.UK Kidney Association.UK Kidney Association.UK Kidney Association.

Terms

Thrill
The buzz felt over a working fistula or graft.The buzz felt over a working fistula or graft.The buzz felt over a working fistula or graft.The buzz felt over a working fistula or graft.
Bruit
The whooshing sound heard over a working access.The whooshing sound heard over a working access.The whooshing sound heard over a working access.The whooshing sound heard over a working access.
Maturation
The weeks to months in which a new fistula widens and strengthens enough for needles.The weeks to months in which a new fistula widens and strengthens enough for needles.The weeks to months in which a new fistula widens and strengthens enough for needles.The weeks to months in which a new fistula widens and strengthens enough for needles.
Stenosis
A narrowing inside a blood vessel.A narrowing inside a blood vessel.A narrowing inside a blood vessel.A narrowing inside a blood vessel.
Thrombosis
A blood clot that blocks the access.A blood clot that blocks the access.A blood clot that blocks the access.A blood clot that blocks the access.
Neointimal hyperplasia
Overgrowth of cells inside the vein wall that narrows the channel.Overgrowth of cells inside the vein wall that narrows the channel.Overgrowth of cells inside the vein wall that narrows the channel.Overgrowth of cells inside the vein wall that narrows the channel.
Steal
Too little blood reaching the hand because the access diverts it.Too little blood reaching the hand because the access diverts it.Too little blood reaching the hand because the access diverts it.Too little blood reaching the hand because the access diverts it.
Patency
How long an access stays open and usable; primary, assisted, and secondary patency count procedures differently.How long an access stays open and usable; primary, assisted, and secondary patency count procedures differently.How long an access stays open and usable; primary, assisted, and secondary patency count procedures differently.How long an access stays open and usable; primary, assisted, and secondary patency count procedures differently.
Rope-ladder
Rotating needle sites along the whole access.Rotating needle sites along the whole access.Rotating needle sites along the whole access.Rotating needle sites along the whole access.
Buttonhole
Reusing the same needle tract each session.Reusing the same needle tract each session.Reusing the same needle tract each session.Reusing the same needle tract each session.
Life-Plan
A written plan for kidney treatment and the succession of accesses over time.A written plan for kidney treatment and the succession of accesses over time.A written plan for kidney treatment and the succession of accesses over time.A written plan for kidney treatment and the succession of accesses over time.
IN.PACT AV Access
A randomized trial of drug-coated balloons for narrowed fistulas.A randomized trial of drug-coated balloons for narrowed fistulas.A randomized trial of drug-coated balloons for narrowed fistulas.A randomized trial of drug-coated balloons for narrowed fistulas.
LOCK IT-100
A randomized trial of a taurolidine/heparin catheter lock.A randomized trial of a taurolidine/heparin catheter lock.A randomized trial of a taurolidine/heparin catheter lock.A randomized trial of a taurolidine/heparin catheter lock.
FAVOURED
A randomized trial of fish oil and aspirin after fistula creation.A randomized trial of fish oil and aspirin after fistula creation.A randomized trial of fish oil and aspirin after fistula creation.A randomized trial of fish oil and aspirin after fistula creation.
V007
A randomized trial comparing a bioengineered vessel with a fistula.A randomized trial comparing a bioengineered vessel with a fistula.A randomized trial comparing a bioengineered vessel with a fistula.A randomized trial comparing a bioengineered vessel with a fistula.
ReferencesMga SanggunianMga TinubdanReng Reperensya 21 sources
  1. Lok, C. E., Huber, T. S., Lee, T., Shenoy, S., Yevzlin, A. S., Abreo, K., Allon, M., Asif, A., Astor, B. C., Glickman, M. H., Graham, J., Moist, L. M., Rajan, D. K., Roberts, C., Vachharajani, T. J., Valentini, R. P., & National Kidney Foundation. (2020). KDOQI clinical practice guideline for vascular access: 2019 update. American Journal of Kidney Diseases, 75(4 Suppl 2), S1–S164. https://doi.org/10.1053/j.ajkd.2019.12.001
  2. Aitken, E., Anijeet, H., Ashby, D., Barrow, W., Calder, F., Dowds, B., Fielding, C., Gilbert, J., Jones, R., Karunanithy, N., Khawaja, Z., Roberts, E., Robson, M., Shroff, R., Stacey, H., Thomson, P., & Waters, D. (2025). UK Kidney Association clinical practice guideline on vascular access for haemodialysis. BMC Nephrology, 26(1), 461. https://doi.org/10.1186/s12882-025-04374-y
  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  4. Lookstein, R., Haruguchi, H., Suemitsu, K., Isogai, N., Gallo, V., Madassery, S., Misra, S., Wang, H., Roffe, P. S., & Holden, A. (2023). IN.PACT AV Access randomized trial of drug-coated balloons for dysfunctional arteriovenous fistulae: Clinical outcomes through 36 months. Journal of Vascular and Interventional Radiology, 34(12), 2093–2102.e7. https://doi.org/10.1016/j.jvir.2023.07.007
  5. Holden, A., Haruguchi, H., Suemitsu, K., Isogai, N., Hull, J., Wiechmann, B. N., Wang, H., Seamans, J., & Lookstein, R. (2026). IN.PACT AV Access randomized trial update: 3-year clinical results by anatomic and demographic subsets and 5-year extension mortality analysis. CVIR Endovascular, 9(1), Article 746. https://doi.org/10.1186/s42155-026-00746-z
  6. Agarwal, A. K., Roy-Chaudhury, P., Mounts, P., Hurlburt, E., Pfaffle, A., & Poggio, E. C. (2023). Taurolidine/heparin lock solution and catheter-related bloodstream infection in hemodialysis: A randomized, double-blind, active-control, phase 3 study. Clinical Journal of the American Society of Nephrology, 18(11), 1446–1455. https://doi.org/10.2215/CJN.0000000000000278
  7. Ko, T.-Y., Wu, C.-C., Hsieh, M.-Y., Yang, C.-W., Cheng, C.-H., Chen, C.-K., & Kao, H.-L. (2025). A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access. Kidney International, 107(2), 348–358. https://doi.org/10.1016/j.kint.2024.10.023
  8. Attia, M. I., Atta, I. M., Essam, S. M., Kamel, A. N., & Hamada, N. M. (2026). Effect of apixaban on early anastomotic stenosis after arteriovenous fistula creation for hemodialysis. The Journal of Vascular Access, 27(4), 1678–1685. https://doi.org/10.1177/11297298251407275
  9. Hussain, M. A., Moore, E. E., Villa, R., Khondker, Z., Niklason, L. E., & Parikh, S. (2026). Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: A multicentre, randomised, controlled, phase 3 trial. The Lancet Digital Health, 8(8), 101036. https://doi.org/10.1016/j.landig.2026.101036
  10. Robbin, M. L., Greene, T., Allon, M., Dember, L. M., Imrey, P. B., Cheung, A. K., Himmelfarb, J., Huber, T. S., Kaufman, J. S., Radeva, M. K., Roy-Chaudhury, P., Shiu, Y.-T., Vazquez, M. A., Umphrey, H. R., Alexander, L., Abts, C., Beck, G. J., Kusek, J. W., & Feldman, H. I. (2018). Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: Findings from the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology, 29(11), 2735–2744. https://doi.org/10.1681/ASN.2017111225
  11. Irish, A. B., Viecelli, A. K., Hawley, C. M., Hooi, L.-S., Pascoe, E. M., Paul-Brent, P.-A., Badve, S. V., Mori, T. A., Cass, A., Kerr, P. G., Voss, D., Ong, L.-M., & Polkinghorne, K. R. (2017). Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: A randomized clinical trial. JAMA Internal Medicine, 177(2), 184–193. https://doi.org/10.1001/jamainternmed.2016.8029
  12. Basile, C., Lomonte, C., Vernaglione, L., Casucci, F., Antonelli, M., & Losurdo, N. (2008). The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrology Dialysis Transplantation, 23(1), 282–287. https://doi.org/10.1093/ndt/gfm549
  13. Percudani, U., Delsante, M., Pastori, G., Shakkour, M., Fiaccadori, E., & Bandera, A. (2026). Ten tips for the management of vascular access in hemodialysis patients. Clinical Kidney Journal, 19(10), sfag366. https://doi.org/10.1093/ckj/sfag366
  14. Centers for Disease Control and Prevention (CDC). (2024, March 29). Best practices for bloodstream infection prevention in dialysis setting. U.S. Department of Health and Human Services. https://www.cdc.gov/dialysis-safety/hcp/clinical-safety/
  15. Chen, D. P., Shi, Y. X., Li, H., Liu, Y. D., Wang, Y. F., Yu, Z. Y., Jiang, H., Ren, J. G., Xue, J., Wang, P., & Ye, C. Y. (2026). Predilation-free scoring paclitaxel-coated balloon versus conventional plain balloon angioplasty for failing arteriovenous access: A multicenter randomized controlled trial. CardioVascular and Interventional Radiology, 49(8), 1507–1516. https://doi.org/10.1007/s00270-026-04515-2
  16. Lindhard, K., Hansen, H. P., Gliese, K., Hansen, E., Hommel, K., Jensen, B. L., Liem, Y., Pedersen, B. L., Pourarsalan, M., Rix, M., Heaf, J., & Hansen, D. (2026). Effect of far infrared radiation on the proportion of interventions in arteriovenous fistulas in patients on hemodialysis: A randomized trial. Clinical Journal of the American Society of Nephrology, 21(8), 1394–1403. https://doi.org/10.2215/CJN.0000001079
  17. Taengsakul, N., Lertutsahakul, P., Pooloui, P., & Buttakosa, M. (2026). Effect of preoperative isometric hand exercise on vascular caliber in patients with advanced chronic kidney disease: A randomised controlled trial. BMC Nephrology, 27(1), Article 5200. https://doi.org/10.1186/s12882-026-05200-9
  18. Ameen, N. K., Albadawi, A. I., Alghamdi, S. K., Atwi, A. I., Alharbi, L. N., Alzahrani, A. M., Alotaibi, T. A., Almaghrabi, A. T., Alghamdi, L. S., & Justaniah, A. I. (2026). Endovascular arteriovenous fistula: Outcomes and comparison with surgical arteriovenous fistula: An updated systematic review and meta-analysis. The Journal of Vascular Access, 27(5), 1925–1954. https://doi.org/10.1177/11297298261424630
  19. Wang, L.-P., Tsai, L.-H., Huang, H.-Y., Okoli, C., & Guo, S.-E. (2022). Effect of buttonhole cannulation versus rope-ladder cannulation in hemodialysis patients with vascular access: A systematic review and meta-analysis of randomized/clinical controlled trials. Medicine, 101(29), e29597. https://doi.org/10.1097/MD.0000000000029597
  20. Pattharanitima, P., Wongwatanasanti, K., Tantiyavarong, P., Chatkrailert, A., Banchonglaksa, W., & Anumas, S. (2026). Comparative efficacy of low-concentration trisodium citrate and low-concentration heparin for locking central venous hemodialysis catheters: A randomized controlled study. Renal Failure, 48(1), 2641842. https://doi.org/10.1080/0886022X.2026.2641842
  21. Kaya, M. H., Büyükturan, Ö., Büyükturan, B., Alkan, H., & Güçlü, A. (2026). Structured exercise improves vascular access and functional outcomes in hemodialysis patients: A randomized controlled trial. Journal of Nephrology, 39(5), 921–930. https://doi.org/10.1093/joneph/aajaf070
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save